ENvue Medical, Inc.
FEED Healthcare Medical Devices
ENvue Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue fell 51.6%, EPS grew 75.8%, free cash flow grew 19.8% and total debt fell 45.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow FEED
ENvue Medical, Inc. (FEED) Altman Z-score
ENvue Medical, Inc.'s Altman Z-score for fiscal 2025 is −4.72, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −4.72 | 24.21 |
| FY2024 | −28.94 | (14.88) |
| FY2023 | −14.06 | 1.15 |
| FY2022 | −15.21 | (8,834.37) |
| FY2022 | 8819.16 | 8,822.35 |
| FY2021 | −3.19 | (6,584.55) |
| FY2021 | 6581.36 | 6,588.86 |
| FY2020 | −7.50 | (3,980.94) |
| FY2020 | 3973.43 | 3,987.35 |
| FY2019 | −13.92 | (28,900.39) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.01 | — | 0.02 | |
| Retained earnings / total assets | (2.20) | — | −3.08 | |
| EBIT / total assets | (0.56) | — | −1.84 | |
| Market value of equity / total liabilities | 0.19 | — | 0.11 | |
| Sales / total assets | 0.06 | — | 0.06 | |
| Altman Z-score | Distress zone | −4.72 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −6.20 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| DHAI DIH Holding US, Inc. compare | −1.8× |
| DYNTQ Dynatronics Corporation compare | −2.3× |
| FEED ENvue Medical, Inc. | −4.7× |
| SSKN Strata Skin Sciences, Inc. compare | −11.5× |
| AFIB Acutus Medical, Inc. compare | −28.5× |
| VJET Flyte Aviation, Inc. compare | −30.6× |
| THMO ThermoGenesis Holdings, Inc. compare | −37.8× |
| NUWE Nuwellis, Inc. compare | −76.4× |
| PFSA PROFUSA, Inc. compare | −83.9× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets